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Abstract
To identify differentially expressed genes in hepatocarcinogenesis, we performed differential display analysis using
surgically resected hepatocellular carcinoma (HCC) and adjacent non-tumorous liver tissues. We identified four cDNA
fragments upregulated in HCC samples, encoding antisecretory factor-1 (AF), gp96, DAD1 and CDC34. Northern blot
analysis demonstrated that these mRNAs were expressed preferentially in HCCs compared with adjacent non-tumorous liver
tissues or normal liver tissues from non-HCC patients. The expression of these mRNAs was increased along with the
histological grading of HCC tissues. These mRNA levels were also high in three human HCC cell lines (HuH-7, HepG2 and
HLF), irrespective of the growth state. We also demonstrate that sodium butyrate, an inducer of differentiation,
downregulated the expression of AF and gp96 mRNAs, supporting in part our pathological observation. Immunohisto-
chemical analysis revealed that gp96 and CDC34 proteins were preferentially accumulated in cytoplasm and nuclei of HCC
cells, respectively. Overexpression of these genes could be an important manifestation of HCC phenotypes and should
provide clues to understand the molecular basis of hepatocellular carcinogenesis. ß 2001 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Hepatocellular carcinoma (HCC) is one of the
most common cancers in the world today. Persistent
hepatitis B virus (HBV) and C virus (HCV) infec-
tions have been closely associated with the develop-
ment of HCC [1,2]. Other causative factors including
dietary consumption of a£atoxins, alcohol and an
iron overload have also been reported [3^5]. Recent
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advances in molecular biology have revealed various
genetic abnormalities in HCC cells. HBV encodes a
protein called X (HBx) that can transactivate several
cellular genes containing a common DNA motif
known as the UB site, and promote transformation
of ¢broblasts as well as liver cells [6^8]. Overexpres-
sion of a HCV core protein can also transform liver
cells [9]. Furthermore, overexpression and allelic am-
pli¢cation of c-myc, mutation in codon 12 or 61 of
H-, K- and N-ras, activation of c-met oncogenes,
aberrations in p53 and Rb tumor-suppressor genes
have been observed in some HCC cells [10^17]. How-
ever, these ¢ndings are, for the most part, depending
on precedent knowledge based on gene analyses in
viruses or other types of cancers. Comprehensive
studies on genetic abnormalities accumulated in the
development of HCC have been rare.
In order to study the wide variety of genetic events
in HCC cells, we have been screening di¡erentially
expressed genes related with human liver carcinogen-
esis [18]. In this study, as an alternative approach, we
used a newly developed di¡erential display (DD)
method [19] to identify di¡erentially expressed genes
between HCC and non-tumorous liver tissues. Even-
tually we identi¢ed four genes whose transcripts were
upregulated speci¢cally along with HCC progression.
2. Materials and methods
2.1. Human liver tissue samples and HCC cell lines
Surgically resected primary HCC and adjacent
non-tumorous liver tissues from patients 1^11 and,
as controls, normal liver tissues from patient N1 who
su¡ered from liver abscess and from patient N2 who
had died of pancreatic cancer, were used. The clin-
icopathological data of HCC patients are summa-
rized in Table 1.
Three human HCC cell lines, HuH-7, HepG2 and
HLF, were obtained from the Japanese Cancer Re-
search Resources Bank.
2.2. Culture of HuH-7, HepG2 and HLF cells
Cells were seeded into 10 cm culture dishes con-
taining Dulbecco’s modi¢ed Eagle’s medium
(DMEM) (Life Technologies) supplemented with
10% fetal bovine serum (FBS). Culture medium
was changed every other day during the experiment.
Total RNAs were extracted from these HCC cell
lines for Northern bot analysis.
Table 1
Clinicopathological characteristics of HCC patients and the tissue samples
Patients Age (years) Sexa Viral statusb Liver histology Tumor size (cm)e
Non-tumorc HCCd
P1 67 M C CH Poorf 3.0
P2 71 M C CH Poorg 7.0
P3 55 M B LC Well 2.1
P4 66 F NBNC Normal Mod 5.4
P5 69 F C LC Mod 4.0
P6 65 M C LC Mod-to-poor 7.5
P7 71 M C LC Mod-to-poor 5.5
P8 57 M C LC Mod 3.0
P9 63 F NBNC LC Well-to-mod 1.6
P10 38 F NBNC CH Mod 8.0
P11 79 F C LC Mod 6.0
aM, male; F, female.
bC, anti-HCV antibody positive; B, HBV surface antigen positive; NBNC, HBV surface antigen and anti-HCV antibody negative.
cNon-tumor, non-tumorous liver tissue; LC, liver cirrhosis ; CH, chronic hepatitis.
dPoor, poorly di¡erentiated; Mod, moderately di¡erentiated; Well, well di¡erentiated HCCs.
eRepresented as the largest diameter.
f A mixture of well-to-moderately and poorly di¡erentiated HCC.
gA mixture of moderately and poorly di¡erentiated HCC.
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2.3. Sodium butyrate treatment
HuH-7 cells were seeded in DMEM supplemented
with 10% FBS and various concentrations of sodium
butyrate (0, 0.5, 3 mM). After a 24 h incubation,
cells were harvested, and total RNA was extracted.
2.4. Di¡erential display of mRNAs
DD was performed using 50 Wg of total RNAs
from HCC and non-tumorous liver tissues of patient
5 as described [19]. Brie£y, total RNA was extracted
from HCC and non-tumorous liver tissues using Iso-
gen (Nippon Gene, Tokyo, Japan). Double-stranded
cDNA was synthesized using oligo(dT)-latex beads
(Takara, Tokyo, Japan). The cDNA was digested
with either NlaIII or Sau3AI and ligated with speci¢c
adapters. Next, this cDNA was digested crosswise
with Sau3AI or NlaIII and ligated with the same
adapter pairs. The ligation product was ampli¢ed
by polymerase chain reaction (PCR) in the presence
of [K-32P]dCTP using 0.5 U of Taq DNA polymerase
(Pharmacia, Uppsala, Sweden) with 16 pairs of prim-
er sets, 5P-CGA ATG TAC AGG ATA CGC CAT
GN-3P and 5P-CAT AGT CAG TTG CGA CAC
GAT CN-3P, where N represents either G, A, T, or
C. The cycling parameters were as follows: 96‡C for
30 s, 56‡C for 30 s, 72‡C for 1 min for 25 cycles,
followed by 72‡C for 10 min. The ampli¢ed cDNAs
were separated on a 6% polyacrylamide sequencing
gel and transferred to Whatman 3MM paper for
autoradiographic exposure. The cDNA fragments
showing a di¡erential intensity between HCC and
non-tumorous liver samples were recovered and re-
ampli¢ed under the same conditions as in the DD
except that no labeled nucleotide was added. PCR
products were run on a 6% polyacrylamide gel,
stained with ethidium bromide, eluted and used as
probes for Northern blot analyses. Ampli¢ed cDNA
fragments were also cloned into a pUC118 vector for
the sequencing analysis.
2.5. Northern blot analysis
Total RNA was denatured and fractionated on a
1.2% agarose gel containing 0.66 M formaldehyde,
transferred to a nylon membrane, then cross-linked
at 80‡C for 2 h. Probe labeling and hybridization
were performed as described previously [20]. Speci¢c
band intensity was quantitated using a Fuji imaging
analysis system, BAS-2000 (Fuji Film, Tokyo, Ja-
pan). We used the Wilcoxon signed rank test to com-
pare the band radiointensities of Northern blot anal-
ysis. Signi¢cance was judged at P6 0.05.
2.6. DNA sequencing and data analysis
Sequence analysis of cDNAs was performed in
both directions using M13 forward and reverse prim-
ers with a £uorescent automated 377XL DNA se-
quencer (Applied Biosystems, Foster City, CA,
USA). The nucleotide sequences were analyzed via
the BLAST program for matches in the GenBank
database.
2.7. Immunohistochemistry
Para⁄n-embedded sections were depara⁄nized.
HuH-7 cells were grown on slide grasses, and ¢xed
with 4% paraformaldehyde. Immunohistochemistry
for albumin, gp96 and Cdc34 proteins was per-
formed using the avidin-biotin-peroxidase complex
method. Sections or plates prepared by this method
were treated with 0.3% H2O2 in methanol to block
endogenous peroxidase. After blocking with 1% skim
milk, the sections were incubated with anti-albumin
(1:200) (Dako Japan, Kyoto, Japan), anti-gp96
(1:100) (Santa Cruz, CA, USA) or anti-Cdc34
(1:50) (Transduction Laboratories, Lexington, KY,
USA) antibodies overnight at 4‡C, then washed in
phosphate-bu¡ered saline solution. Biotinylated
anti-rabbit, anti-goat or anti-mouse IgG, used as sec-
ondary antibodies, were added and allowed to react
for 60 min at room temperature, followed by strept-
avidin-biotinylated peroxidase complex (Vector, Bur-
lingame, CA, USA) for 30 min at room temperature.
The sections were incubated with diaminobenzidine-
hydrogen peroxide to visualize the reaction products.
3. Results
3.1. Isolation of di¡erential cDNAs between human
HCC and non-tumorous liver tissues
DD was performed to identify di¡erentially ex-
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pressed genes between HCC and adjacent non-tu-
morous liver tissues from patient 5, as described pre-
viously [19]. Isolated cDNAs were further examined
by Northern blot analysis using several HCC sam-
ples. Consequently, we focused on antisecretory fac-
tor-1 (AF) (GenBank accession No. U24704), gp96
(X15187), DAD1 (D15057) and CDC34 (L22005)
mRNAs, which were overexpressed signi¢cantly in
HCC compared with non-tumorous liver tissues.
3.2. Comparison of mRNA expression in surgically
resected human liver tissues
To con¢rm di¡erential expression of mRNAs,
Northern blot analysis using total RNAs from 11
HCC and two non-HCC patients was performed.
As shown in Fig. 1A, the expression of AF, gp96,
DAD1 and CDC34 mRNAs was signi¢cantly higher
in at least eight or nine HCC tissues than in adjacent
non-tumorous tissues. Although the levels of gp96
and DAD1 in patient N2 were relatively high com-
pared with those of patient N1, these £uctuations of
mRNA levels in normal liver tissues were within the
range of those in non-tumorous liver tissues from
HCC-bearing patients.
In order to analyze these mRNA levels quantita-
tively, the radiointensity of each mRNA was mea-
sured and the HCC/non-tumorous liver (H/L) ratios
relative to that of L2-microglobulin (L2m) were plot-
ted in Fig. 1B. Overexpression of these four mRNAs
in HCC tissues was statistically signi¢cant (P6 0.05).
We investigated the correlation between H/L ratios
and histological grading. Pathological information
indicated that the HCC tissue from patient 1 is a
Fig. 1. (A) Northern blot analysis using 10 Wg of total RNAs from human HCC and surrounding non-tumorous liver tissues from 11
HCC patients (P1^P11), and normal liver from non-HCC patients (N1 and N2) as controls. Each number at the top of the panel indi-
cates a single patient. L, H and N denote non-tumorous liver, HCC and normal liver, respectively. In each analysis, identical mem-
branes were hybridized with AF, gp96, DAD1, CDC34 and L2-microglobulin (L2m) probes as the control, respectively. Each mRNA
size (kb) is on the right side. A representative gel stained with ethidium bromide (EtBr) is shown in the bottom panel. (B) HCC/non-
tumorous liver (H/L) ratios of mRNA levels. Ratios were normalized by dividing with the equivalent ratio of L2-microglobulin. Each
circle represents a patient. W denotes well di¡erentiated HCC tissue including P3 (a) ; W/M, well-to-moderately di¡erentiated HCC
tissue, P9 (double striped circle); M, moderately di¡erentiated HCC tissues, P4 (b), P5 (i), P8 (a), P10 (striped circle) and P11 (dou-
ble striped circle) ; P, poorly di¡erentiated P1 (double striped circle) and P2 (a) ; M/P, moderately-to-poorly di¡erentiated HCC tis-
sues, P6 (b) and P7 (striped circle), respectively. The mean H/L ratio of each transcript is shown (999).
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mixture of well-to-moderately and poorly di¡erenti-
ated HCC, and from patient 2 is a mixture of mod-
erately and poorly di¡erentiated HCC (Table 1). We
tentatively classi¢ed them as poorly di¡erentiated
HCC, since the expression of mRNAs associated
with dedi¡erentiation would be attributable to the
higher grade portion of HCC tissues. As shown
Fig. 1B, the average H/L ratios for AF, gp96,
CDC34 and DAD1 were relatively higher in poorly
and moderately-to-poorly di¡erentiated HCCs (pa-
tients 1, 2, 6 and 7), lower in well and well-to-mod-
erately di¡erentiated HCC (patients 3 and 9) and
intermediate in most of the moderately di¡erentiated
HCCs (patients 5, 8 and 11), though the ratios for
these cDNAs remained at basal levels in a moder-
ately di¡erentiated HCC of patients 4 and 10.
These results demonstrate that high expression of
AF, gp96, DAD1 and CDC34 might be associated
with HCC progression. These mRNA levels seemed
to be well correlated with the histological grading.
3.3. Expression of mRNAs in HCC cell lines
Then we examined the expression of these four
mRNAs in human HCC cell lines, HuH-7, HepG2
and HLF. Northern blot analysis using total
RNAs showed that the levels of these four
mRNAs in all three HCC cell lines were higher
than in normal liver tissues, consistent with the
results using HCC tissues (Fig. 2A). In the pre-
vious study, we demonstrated that some di¡erential
cDNAs in HCC cells are regulated depending on
growth conditions of tumor cells [18]. The expres-
sion of the four cDNAs was therefore examined in
HepG2 cells in di¡erent growth conditions (Fig.
2B). HepG2 cells grew rapidly in 10% FBS until
they formed a con£uent monolayer. The level of
cyclin A mRNA, as an indicator of proliferating
HCC cells [21], was high in rapidly growing
HepG2 cells in 10% serum (lane 1), whereas it
was signi¢cantly suppressed in growth-inhibited
cells at higher cell density (lane 2). In subcon£uent
cultures containing 0.1% serum, cells grew slowly,
but the growth rate was not as slow as that of
overcrowded cells (not shown). In these cells, cyclin
A mRNA was not markedly reduced (lane 3). In
contrast, the expression of AF, gp96, DAD1 and
CDC34 mRNAs was constitutively high in both
Fig. 2. (A) Northern blot analysis using total RNAs from human HCC cell lines (HuH-7, HepG2 and HLF) and human normal liver
tissues. RNAs from normal liver tissues (N) of non-HCC patients N1 and N2 were used as controls. Identical membranes were hy-
bridized with AF, gp96, DAD1, CDC34 and L2m probes, respectively. (B) Northern blot analysis using 10 Wg of total RNAs from
HepG2 cells in subcon£uent (lane 1), con£uent (lane 2) in 10% serum and subcon£uent in 0.1% serum (lane 3). Identical membranes
were hybridized with AF, gp96, DAD1, CDC34, L2m and cyclin A, respectively.
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rapidly growing and growth-arrested cells in 10%
and 0.1% serum, respectively. We also performed
these experiments using HuH-7 cells and obtained
the same results (not shown).
3.4. Expression of mRNAs in HuH-7 cells treated
with sodium butyrate
Our results in Fig. 1B suggest that the expression
Fig. 3. (A) Northern blot analysis using total RNAs from HuH-7 cells treated with sodium butyrate. The concentration of sodium bu-
tyrate (mM) is indicated at the top. Identical membranes were hybridized with AF, gp96, DAD1, CDC34, L2m, AFP and cyclin A
probes, respectively. (B) Radiointensity of relative mRNA levels (%). Ratios were normalized by that of L2m. The concentrations of
sodium butyrate in the medium are 0 mM (white), 0.5 mM (gray) and 3 mM (black). (C) Albumin immunohistochemistry of Na-buty-
rate (0.5 mM) treated (right) or untreated (left) HuH-7 cells ; magni¢cation, U300.
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Fig. 4. Sections of moderately di¡erentiated HCC (B,D,F) and surrounding non-tumorous liver (NL) (A,C,E) from patient 8. Sections
of well-to-moderately di¡erentiated HCC (G) and moderately-to-poorly di¡erentiated HCC (H, right) and adjacent non-tumorous liver
(H, left). Sections A and B were stained with hematoxylin and eosin (HE); magni¢cation, U150. Sections C, D, G and H were immu-
nostained with polyclonal antibody against human gp96; E and F were immunostained with monoclonal antibody against human
CDC34; magni¢cation, U300.
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of AF, gp96, DAD1 and CDC34 mRNAs could be
correlated with the di¡erentiation status of HCC
cells. To evaluate whether the mRNA expression is
correlated with liver cell di¡erentiation, we per-
formed Northern blot analysis using total RNAs
from HuH-7 cells treated with sodium butyrate, an
inducer of di¡erentiation of HCC cells [22]. As al-
ready reported [22], the growth rate of HuH-7 cells
was markedly reduced by sodium butyrate dose-de-
pendently (the doubling time was reduced from 32 h
to 41 h by 0.5 mM and to 590 h by 3 mM of sodium
butyrate; data not shown). Accordingly, the expres-
sion of cyclin A was suppressed by sodium butyrate
in HuH-7 cells (Fig. 3A,B). We further demonstrated
that the mRNA expression of K-fetoprotein (AFP)
was decreased (Fig. 3A,B), while cytoplasmic albu-
min immunostaining was markedly increased (Fig.
3C) in HuH-7 cells after butyrate treatment, suggest-
ing that the agent successfully induced di¡erentiated
phenotypes in the cells. The mRNA levels of AF and
gp96 were reduced by butyrate in a dose-dependent
manner, similar to that of AFP mRNA (Fig. 3A,B).
However, in contrast with the expression of cyclin A,
the expression of AF and gp96 mRNAs was consti-
tutively high irrespective of the growth state in HuH-
7 cells (Fig. 2B). We also con¢rmed that the expres-
sion of AFP mRNA was constitutively high in
growth-arrested HuH-7 cells (not shown). Therefore,
the reduced expression of AF and gp96 mRNAs in
butyrate-treated HuH-7 cells was not simply associ-
ated with the cell growth rate. On the other hand, the
expression of DAD1, CDC34 and L2m, as a control,
was una¡ected by butyrate. These results suggest
that the high levels of AF and gp96 mRNAs are
correlated with dedi¡erentiation of HCC cells.
3.5. Immunohistochemistry of gp96 and Cdc34
proteins
To see the protein level and in vivo manifestation,
we performed an immunohistochemical analysis for
gp96 and Cdc34 to determine their localization in
liver tissue from patient 8. As shown in Fig. 4, cyto-
plasmic gp96 immunostaining was markedly in-
creased in HCC cells (Fig. 4D) in comparison with
that in adjacent non-tumorous liver cells (Fig. 4C).
On the other hand, nuclear staining for Cdc34 was
observed in some HCC cells (Fig. 4F, arrows), but
not in non-tumorous liver cells (Fig. 4E), whereas the
reactions for both proteins were negative in ¢bro-
blasts in the stroma and in the in¢ltrated lympho-
cytes.
To compare the immunoreactivity for gp96 among
HCCs of di¡erent histological grades, we performed
immunostaining of para⁄n-embedded HCC tissues
from 13 other patients. All of these HCC tissues
were more immunostained with gp96 antibody than
adjacent non-tumorous liver tissues. Representative
results of well-to-moderately di¡erentiated and mod-
erately-to-poorly di¡erentiated HCCs were shown
(Fig. 4G,H, respectively). Similar to the result of
patient 8 (Fig. 4C,D), cytoplasmic gp96 immunos-
tained granules were markedly increased in number
in HCC cells (Fig. 4H, right) in comparison with
non-tumorous liver cells (Fig. 4H, left). Furthermore,
we observed the tendency that poorly or moderately-
to-poorly di¡erentiated HCCs (Fig. 4H, right) exhib-
ited a larger and rougher granular pattern in immu-
nostaining for gp96 in comparison with moderately
(Fig. 4D), well or well-to-moderately di¡erentiated
(Fig. 4G) HCCs.
4. Discussion
Our results demonstrated that AF, gp96, DAD1,
and CDC34 mRNAs were preferentially expressed in
HCC tissues relative to non-tumorous liver tissues.
We have reported previously that the expression of
some mRNAs was di¡erentially regulated depending
on cell-cell contact, serum growth factors, or other
growth conditions [18]. However, the present results
demonstrated that higher expression of AF, gp96,
DAD1 and CDC34 mRNAs in HCC cells was not
simply re£ecting growth states of the HCC cells. As
mentioned above, the expression of these mRNAs in
a HCC sample from patients 4 and 10 were very low
compared to that in other moderately di¡erentiated
HCC samples. This may be associated with the ex-
traordinary case history of these patients; the pri-
mary tumor had developed without virus infection
and cirrhosis compared to other HCCs. Therefore,
constitutive upregulation of these mRNAs in moder-
ately di¡erentiated HCCs may be correlated speci¢-
cally with the chronic process of HCC development.
Further upregulation of AF, gp96, DAD1 and
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CDC34 mRNAs was observed in poorly and moder-
ately-to-poorly di¡erentiated HCCs, suggesting that
the expression is also associated with dedi¡erentia-
tion of HCC cells. This is, in part, supported by the
fact that the expression of AF and gp96 mRNAs was
downregulated in HuH-7 cells treated with sodium
butyrate. However, inconsistent with the pathologi-
cal observation, sodium butyrate did not a¡ect the
levels of DAD1 and CDC34 mRNAs, suggesting
that it may be a possible agent inducing some, but
not all, of the di¡erentiating properties. Further-
more, immunohistochemical analysis con¢rmed the
upregulation of gp96 and Cdc34 at the protein levels
and demonstrated that they were preferentially lo-
cated in the cytoplasm and nuclei of HCC cells, re-
spectively. We also observed the tendency that
poorly di¡erentiated HCCs exhibited a larger and
rougher granular pattern in immunostaining for
gp96 in comparison with that of moderately or well
di¡erentiated HCCs. Therefore, these manifestations
could be a useful marker for the histological diagno-
sis of HCCs.
gp96, also known as GRP94, is a member of the
heat shock protein family localized predominantly in
the endoplasmic reticulum (ER) and, in part, the cell
surface [23,24]. The expression is induced by glucose
starvation, radiation, interferons (INFs), and inter-
leukin 6 (IL-6) [25^28]. In the normal liver from
patient N2, who had died of pancreatic cancer, a
relatively higher level of gp96 mRNA was observed.
This may be caused by adjuvant irradiation therapy
which is, in general, recommended after resection of
pancreatic cancer. It has been hypothesized that gp96
is a chaperone like GRP78/Bip [29], which is also
highly expressed in HCCs (M. Shuda, in prepara-
tion). Both genes have several regulatory elements
in common in the promoter region, and are induced
in coordination by the presence of malfolded pro-
teins in ER [30,31]. Interestingly, gp96 closely resem-
bles tumor-associated heparanase, which has a key
role in tumor progression and metastasis [32,33].
This may be associated with the fact that IL-6 can
induce gp96 in metastatic breast cancer, but not in
the primary cells, and also that tumorigenicity of
colon carcinoma cells is increased by gp96 [28,34].
In addition, gp96 has anti-apoptotic activity [35].
Paradoxically, immunogenic peptide-bound gp96,
rather than gp96 itself, could be a tumor-rejection
antigen [36^38]. Therefore, gp96 could have pleiotro-
pic e¡ects capable of rendering malignant potential
to tumor cells while evoking an anti-tumor immune
response.
CDC34, also called UBC3, encodes a ubiquitin
conjugating enzyme that participates in the ubiqui-
tin-mediated proteolysis of several cyclins or cyclin-
dependent kinase (CDK) inhibitors including
p27Kip1, and has been shown to play an important
role in the regulation of cell cycle progression [39^
42]. Since reduced expression of p27Kip1 is correlated
with the poor prognosis of several carcinomas in-
cluding HCC [43^48], upregulation of CDC34 could
promote tumor progression by degrading of p27Kip1
in HCC cells. CDC34 is also involved in the degra-
dation of IUB-K, an inhibitor of transcription factor
NFUB [49]. Since activated NFUB blocks Fas-associ-
ated apoptosis in liver cells, CDC34 may exert anti-
apoptotic activity by reducing the level of functional
IUB-K [50]. It has been known that CDC34 is local-
ized in both the nucleus and the cytoplasm [51];
however, our results demonstrated that CDC34 was
preferentially accumulated in some nuclei of HCC
cells. This may be in line with the observation that
CDC34 co-localizes with the mitotic spindle in ana-
phase cells of lower populations [51]. The other pos-
sibility is that our monoclonal antibody for CDC34
may not e¡ectively detect the antigen in formalin
¢xed tissue samples and only a few cells which ex-
pressed higher levels of CDC34 were immunostained.
Therefore, our results suggest that the molecule may
contribute to spindle function at a late stage of mi-
tosis in HCC cells.
AF is a protein secreted from human pituitary
gland [52]. This is a potent inhibitor of intestinal
hypersecretion and in£ammation induced by cholera
toxin [53]. Interestingly, the amino acid sequence of
AF is virtually identical to that of human S5a, a
ubiquitin conjugate binding subunit of 26S protease,
although the two mRNAs di¡er in their 5P untrans-
lated region [52,54]. Our reverse transcription (RT)-
PCR analysis using speci¢c primer pairs for both
cDNAs revealed that only a transcript representing
AF could be detected in liver tissues from HCC pa-
tients (not shown). However, their structural identity
suggests that the two gene products could share com-
mon functions. Ubiquitin-mediated proteolysis is in-
volved in many cellular processes including cell cycle
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progression and transcriptional regulation [55,56]. A
homologue of this gene has also been identi¢ed as
the p44 subunit of the basal transcription factor IIH
(TFIIH) [57]. Furthermore, S5a can interact with
Id1, a negative regulator for the basic helix-loop-he-
lix transcription factors, and reverse Id1-mediated
repression [58]. These facts suggest that the AF/S5a
protein could be a potential regulator of transcrip-
tion factors important for HCC progression. Our
results demonstrated the overexpression of compo-
nents of the ubiquitin-proteasome system, including
AF/S5a and Cdc34, in HCCs. This could support the
previous report that protein ubiquitination is acti-
vated in HCC cells [59]. These ¢ndings suggest that
comprehensive remodeling of the gene regulation sys-
tem at the posttranslational level may be involved in
HCC progression.
The DAD1 gene was identi¢ed originally as a de-
fender against apoptotic death gene in a mutant
hamster cell line, with no sequence similarity to any
other known cell death suppressor genes [60]. DAD1
mRNA is downregulated in human prostatic tumor
cells when they undergo apoptosis by staurosporine,
a potent inhibitor of protein kinases [61]. This gene
encodes ubiquitously expressed hydrophobic rough
ER protein, which consists of 113 amino acids and
is a subunit of the mammalian oligosaccharyltrans-
ferase (OST) catalyzing N-linked glycosylation of
many nascent polypeptides in the ER [62]. Inhibition
of this enzyme by tunicamycin can induce apoptosis
in human promyelocytic HL-60 cells [63]. Therefore,
high expression of DAD1 in HCC cells can activate
OST and block apoptosis, thereby enhancing tumor
cell survival.
It has been proposed that aberrations of the anti-
oncogenes, including p53 and Rb, are common
events in advanced liver malignancies [17,64,65]. On
the other hand, though there are exceptions in ani-
mal systems, the extensive contribution of major on-
cogenes, including the ras family, has not yet been
established in human HCCs [66,67]. Using the DD
method, we have identi¢ed several genes overex-
pressed in HCC cells. Functional analysis of these
genes could provide further insight into understand-
ing liver carcinogenesis. Furthermore, these genes
should be used as tumor markers for diagnosis or
indices for the prognosis of HCC patients.
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